 CHICAGO--BUSINESS WIRE--MAIA Biotechnology, Inc., NYSE American: MAIA MAIA, the Company, a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that it will present the results of a study of the anticancer agent 6-thio-dG THIO in hepatocellular carcinoma HCC in vitro and in vivo models at the EORTC-NCI-AACR ENA Symposium on Molecular Targets and Cancer Therapeutics. The symposium is taking place Oct. 26-28, 2022 